{"entity":{"id":"azenosertib","kind":"drug","name":"Azenosertib","aka":["ZN-c3"],"tldr":"Azenosertib is an experimental small-molecule drug from K-, Beta in phase 3 trials for ovarian cancer, aimed at WEE1.","summary":"Azenosertib is a small-molecule drug developed by K-, Beta. Its target is WEE1 (the sponsor names WEE1). The sponsor states: Azenosertib (ZN-c3) is a selective, orally bioavailable WEE1 inhibitor that promotes premature cell-cycle progression and DNA damage/mitotic catastrophe in tumours with high cyclin E1 expression; tested against investigator's choice chemotherapy in platinum-resistant, cyclin E1-positive ovarian, primary peritoneal, or fallopian tube cancer. ClinicalTrials.gov describes the intervention as: Azenosertib 400 mg will be administered orally. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07546500 (A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression), in ovarian cancer. The largest, NCT07546500, plans to enrol 420 participants with primary completion expected 2028-05-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Azenosertib","url":"https://clinicaltrials.gov/search?intr=Azenosertib"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":["wee1"],"drugs":[],"companies":["zentalis-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07546500","nct05128825"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"small molecule","mechanism":"Azenosertib (ZN-c3) is a selective, orally bioavailable WEE1 inhibitor that promotes premature cell-cycle progression and DNA damage/mitotic catastrophe in tumours with high cyclin E1 expression; tested against investigator's choice chemotherapy in platinum-resistant, cyclin E1-positive ovarian, primary peritoneal, or fallopian tube cancer.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/azenosertib/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"target":[{"id":"wee1","kind":"target","name":"WEE1","route":"/targets/wee1/"}],"company":[{"id":"zentalis-pharmaceuticals","kind":"company","name":"Zentalis Pharmaceuticals","route":"/companies/zentalis-pharmaceuticals/"}],"trial":[{"id":"nct05128825","kind":"trial","name":"A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer","route":"/trials/nct05128825/"},{"id":"nct07546500","kind":"trial","name":"A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression","route":"/trials/nct07546500/"}]}}